高速分拣大细胞的泵
|
By LabMedica International staff writers Posted on 25 Aug 2017 |

图片:微流控芯片能够以16微秒的高速分拣细胞。放大视图展示了片上分拣小眼虫细胞(图片蒙名古屋大学惠赐)。
许多医疗应用场合必须分拣单个细胞,包括从细胞悬液中分离特定的细胞类型。科研人员已经用荧光活化细胞分拣(FACS)做高通量细胞分拣。
较大细胞的FACS要求在低压下处理样本,让样本通过更宽的喷嘴,以防止损坏,因此分拣受限于低水平通量。用激光激励液滴中细胞的自体荧光或标记荧光,然后使液滴发生偏转,按照不同特性进入不同容器。因为产生的喷雾剂导致样本感染,所以这项技术引人担忧。
日本名古屋大学的科学家研究细胞分拣时用一颗微流控芯片预防样本感染。这颗芯片有微通道,将细胞悬液导入微通道进行分拣。科研小组在微流控芯片里集成了两只外部驱动的片上泵,以实现高速的流控制。他们用一只高速发动器作为泵的动力源,成功生成了一股持续16微秒的液流,进行细胞分拣。
虽然提出了各种片上细胞分拣方法,但是大细胞的高通量分拣仍受制于在大范围分拣区内控制高速液流的困难。为克服这一难题,科研小组提出把压电发动器放在微流控芯片外,用它驱动双膜泵,实现高速的局部流控制。他们评估了把液流特征换成局部流的可控性。
他们用这项技术不仅能分拣大细胞,还能分拣小细胞,而且速度快,纯度高,活力强。以100微米左右的微藻类为例测试该方法,得到95.8%的纯度、90.8%的存活率和92.8%的成功率。他们用24微米左右的癌细胞作为小细胞的模型,得到了98.9%的纯度、90.7%的存活率和97.8%的成功率。
该研究的论文发表于2017年6月14日的《芯片实验室》杂志。领衔作者、助理教授Shinya Sakuma博士说:“微流控芯片拥有十字形分拣区和有三个分支的微流控通道。主通道里的靶体/非靶体细胞在三个维度上对齐。当检测到靶细胞时,片上泵迅速启动,把细胞拣入两条兴趣通道之一。同时,把非靶细胞冲入废料通道,泵不发动。
Related Links:
名古屋大学
较大细胞的FACS要求在低压下处理样本,让样本通过更宽的喷嘴,以防止损坏,因此分拣受限于低水平通量。用激光激励液滴中细胞的自体荧光或标记荧光,然后使液滴发生偏转,按照不同特性进入不同容器。因为产生的喷雾剂导致样本感染,所以这项技术引人担忧。
日本名古屋大学的科学家研究细胞分拣时用一颗微流控芯片预防样本感染。这颗芯片有微通道,将细胞悬液导入微通道进行分拣。科研小组在微流控芯片里集成了两只外部驱动的片上泵,以实现高速的流控制。他们用一只高速发动器作为泵的动力源,成功生成了一股持续16微秒的液流,进行细胞分拣。
虽然提出了各种片上细胞分拣方法,但是大细胞的高通量分拣仍受制于在大范围分拣区内控制高速液流的困难。为克服这一难题,科研小组提出把压电发动器放在微流控芯片外,用它驱动双膜泵,实现高速的局部流控制。他们评估了把液流特征换成局部流的可控性。
他们用这项技术不仅能分拣大细胞,还能分拣小细胞,而且速度快,纯度高,活力强。以100微米左右的微藻类为例测试该方法,得到95.8%的纯度、90.8%的存活率和92.8%的成功率。他们用24微米左右的癌细胞作为小细胞的模型,得到了98.9%的纯度、90.7%的存活率和97.8%的成功率。
该研究的论文发表于2017年6月14日的《芯片实验室》杂志。领衔作者、助理教授Shinya Sakuma博士说:“微流控芯片拥有十字形分拣区和有三个分支的微流控通道。主通道里的靶体/非靶体细胞在三个维度上对齐。当检测到靶细胞时,片上泵迅速启动,把细胞拣入两条兴趣通道之一。同时,把非靶细胞冲入废料通道,泵不发动。
Related Links:
名古屋大学
Latest 实验室技术 News
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Obtaining tumor tissue can be difficult, and standard genome and RNA... Read more
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more




.jpg)



